

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14,
15, 16, 18, 19, 20, 23, 26 AND 27

1. The following substances and products, namely -

(a) Bufotenine

Cannabinol

Cannabinol derivatives not being Dronabinol or its stereoisomers

Cannabis and cannabis resin

Cathinone

Coca leaf

Concentrate of poppy-straw

Eticyclidine

Etryptamine

Fungus (of any kind) which contains psilocin or and ester of psilocin

Lysergamide

Lysergide and other *N*-alkyl derivatives of lysergamide

Mescaline

Methcathinone

Psilocin

Raw opium

Rolicyclidine

Tenocyclidine

4-Bromo-2,5-dimethoxy- α -methylphenethylamine

N,N-Diethyltryptamine

N,N-Dimethyltryptamine

2,5-Dimethoxy- α -4-dimethylphenethylamine

N-Hydroxy-tenamphetamine

4-Methyl-aminorex

- (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

- (c) the following phenethylamine derivatives, namely -

Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo- β ,2,5-trimethoxyphenethylamine
N-(4-*sec*-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy- α -methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 β -Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(α -Methyl-3,4-methylenedioxyphenethylamino)ethanol
 α -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 α -Methyl-4-(methylthio)phenethylamine
 β ,3,4,5-Tetramethoxyphenethylamine
 β ,2,5-Trimethoxy-4-methylphenethylamine

- (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α -methylphenethylamine, an *N*-alkyl- α -methylphenethylamine, α -ethylphenethylamine, or an *N*-alkyl- α -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
 - (e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
 - (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
 - (vi) by replacement of the *N*-propionyl group by another acyl group;
 - (f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say -
 - (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an *N*-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1.
 3. Any ester or ether of a substance specified in paragraph 1 or 2.
 4. Any salt of a substance specified in any of paragraphs 1 to 3.
 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

SCHEDULE 2

Regulation 3

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14,
15, 16, 18, 19, 20, 21, 23, 26 AND 27

1. The following substances and products, namely -

Acetorphine	Levomoramide
Alfentanil	Levophenacymorphan
Allylprodine	Levorphanol
Alphacetylmethadol	Lofentanil
Alphameprodine	Medicinal opium
Alphamethadol	Metazocine
Alphaprodine	Methadone
Anileridine	Methadyl acetate
Benzethidine	Methyldesorphine
Benzylmorphine (3-benzylmorphine)	Methyldihydromorphine (6-methyldihydromorphine)
Betacetylmethadol	Metopon
Betameprodine	Morpheridine
Betamethadol	Morphine
Betaprodine	Morphine methobromide, morphine <i>N</i> -oxide and other pentavalent nitrogen morphine derivatives
Bezitramide	
Carfentanil	Myrophine
Clonitazene	Nicomorphine
Cocaine	Noracymethadol
Desomorphine	Norlevorphanol
Dextromoramide	Normethadone
Diamorphine	Normorphine
Diampromide	Norpipanone
Diethylthiambutene	Oxycodone
Difenoxin	Oxymorphone
Dihydrocodeinone	Pethidine
<i>O</i> -carboxymethyloxime	Phenadoxone
Dihydroetorphine	
Dihydromorphine	Phenampromide
Dimenoxadole	Phenazocine
Dimepheptanol	Phencyclidine

Dimethylthiambutene	Phenomorphane
Dioxaphetyl butyrate	Phenoperidine
Diphenoxylate	Piminodine
Dipipanone	Piritramide
Dronabinol	Proheptazine
Drotebanol	Properidine
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine	Racemethorphan
	Racemoramide
	Racemorphan
	Remifentanyl
Ethylmethylthiambutene	Sufentanyl
Etonitazene	Thebacon
Etorphine	Thebaine
Etoxeridine	Tilidate
Fentanyl	Trimeperidine
Furethidine	Zipeprol
Hydrocodone	4-Cyano-2-dimethylamino-4,4-diphenylbutane
Hydromorphanol	4-Cyano-1-methyl-4-phenylpiperidine
Hydromorphone	2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid
Hydroxypethidine	
Isomethadone	α -Methylphenethylhydroxylamine
Ketobemidone	1-Methyl-4-phenylpiperidine-4-carboxylic acid
Levomethorphan	4-Phenylpiperidine-4-carboxylic acid ethyl ester

- Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.
- Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.
- Any salt of a substance specified in any of paragraphs 1 to 3.
- Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
- The following substances and products, namely -

Acetyldihydrocodeine	Methaqualone
Amphetamine	Methylamphetamine

Codeine	Methylphenidate
Dextropropoxyphene	Nicocodine
Dihydrocodeine	Nicodicodine (6-nicotinoyldihydrocodeine)
Ethylmorphine (3-ethylmorphine)	Norcodeine
Fenethylamine	Phenmetrazine
Glutethimide	Pholcodine
Lefetamine	Propiram
Mecloqualone	Quinalbarbitone

7. Any stereoisomeric form of a substance specified in paragraph 6.
8. Any salt of a substance specified in paragraph 6 or 7.
9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5

SCHEDULE 3

Regulation 3

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15
(EXCEPT TEMAZEPAM), 16,18,22,23,24,26 AND 27

1. The following substances, namely:-

- | | |
|-------------------|----------------------|
| (a) Benzphetamine | Meprobamate |
| Buprenorphine | Methylphenobarbitone |
| Cathine | Methyprylone |
| Chlorphentermine | Midazolam |
| Diethylpropion | Pentazocine |
| Ethchlorvynol | Phendimetrazine |
| Ethinamate | Phentermine |
| Flunitrazepam | Pipradrol |
| Mazindol | Temazepam |
| Mephentermine | |

(b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

2. Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.
3. Any salt of a substance specified in paragraph 1 or 2.
4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

SCHEDULE 4

Regulation 3

PART I

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1. The following substances and products, namely -

Alprazolam	Ketazolam
Aminorex	Loprazolam
Bromazepam	Lorazepam
Brotizolam	Lormetazepam
Camazepam	Medazepam
Chlordiazepoxide	Mefenorex
Clobazam	Mesocarb
Clonazepam	Nimetazepam
Clorazepic acid	Nitrazepam
Clotiazepam	Nordazepam
Cloxazolam	Oxazepam
Delorazepam	Oxazolam
Diazepam	Pemoline
Estazolam	Pinazepam
Ethyl loflazepate	Prazepam
Fencamfamin	Pyrovalerone
Fenproporex	Tetraazepam
Fludiazepam	Triazolam
Flurazepam	<i>N</i> -Ethylamphetamine
Halazepam	Zolpidem
Haloxazolam	
4 Hydroxy-n-butyric acid	
Ketamine	

2. Any stereoisomeric form of a substance specified in paragraph 1.

3. Any salt of a substance specified in paragraph 1 or 2.

4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

PART II

CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT; EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM THE PROHIBITION ON IMPORTATION AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM OF A MEDICINAL PRODUCT BY ANY PERSON FOR ADMINISTRATION TO HIMSELF; AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1. The following substances, namely -

4 -Androstene-3, 17-dione	Methenolone
5-Androstene-3,17 diol	Methyltestosterone
Atamestane	Metribolone
Bolandiol	Mibolerone
Bolasterone	Nandrolone
Bolazine	19-Nor-4-Androstene-3,17 dione
Boldenone	19-Nor-5-Androstene-3,17 diol
Bolenol	Norboletone
Bolmantalate	Norclostebol
Calusterone	Norethandrolone
4-Chloromethandienone	Ovandrotonone
Clostebol	Oxabolone
Drostanolone	Oxandrolone
Enestobol	Oxymesterone
Epitiostanol	Oxymetholone
Ethyloestrenol	Prasterone
Fluoxymesterone	Propetandrol
Formebolone	Quinbolone
Furazabol	Roxibolone
Mebolazine	Silandrone
Mepitiostane	Stanolone
Mesabolone	Stanozolol
Mestanolone	Stenbolone
Mesterolone	Testosterone
Methandienone	Thiomesterone
Methandriol	Trenbolone

2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestrane-3-one by modification in any of the following ways, that is to say -

- (a) by further substitution at position 17 by a methyl or ethyl group;
- (b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
- (c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
- (d) by fusion of ring A with a heterocyclic system.

3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.

4. The following substances, namely –

Chorionic Gonadotrophin (HCG)

Clenbuterol

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.

6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.

7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.

CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1.-(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.

6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.

7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.

8. Any powder of ipecacuanha and opium comprising-

10% opium, in powder,

10% ipecacuanha root, in powder, well mixed with

80% of any other powdered ingredient containing no controlled drug.

9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.